Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on ABBVIE INC.
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With A..
MT
09/02ABBVIE : SVB Leerink Adjusts AbbVie PT to $142 From $148, Maintains Outperform Rating
MT
08/23ABBVIE : Cowen Adjusts AbbVie's Price Target to $130 From $120, Reiterates Outperform Rati..
MT
08/20ABBVIE : SVB Leerink Adjusts AbbVie's Price Target to $148 from $145, Keeps Outperform Rat..
MT
08/02ABBVIE : JPMorgan Adjusts AbbVie Price Target to $140 From $135, Maintains Overweight Rati..
MT
08/02ABBVIE : Goldman Sachs Adjusts AbbVie Price Target to $112 From $115, Maintains Neutral Ra..
MT
08/02ABBVIE : Barclays Adjusts AbbVie's Price Target to $112 From $105, Keeps Equal-Weight Rati..
MT
08/02ABBVIE : Mizuho Securities Adjusts AbbVie's Price Target to $131 From $128, Maintains Buy ..
MT
07/27ABBVIE : Truist Assumes Coverage of AbbVie With Buy Rating, $118 Price Target
MT
07/02ABBVIE : Daiwa Securities Starts AbbVie at Outperform With $126 Price Target
MT
05/12ABBVIE : UBS Adjusts AbbVie's Price Target to $126 From $124, Maintains Buy Rating
MT
05/03ABBVIE : Mizuho Securities Adjusts AbbVie's Price Target to $128 From $126, Maintains Buy ..
MT
05/03ABBVIE : BMO Capital Adjusts AbbVie PT to $129 From $127, Maintains Outperform Rating
MT
03/30ABBVIE : SVB Leerink Adjusts AbbVie's Price Target to $144 From $140, Maintains Outperform..
MT
02/04ABBVIE : Mizuho Adjusts AbbVie's Price Target to $126 From $117, Reiterates Buy Rating
MT
02/04ABBVIE : SVB Leerink Adjusts Price Target on AbbVie to $140 From $128, Maintains Outperfor..
MT
02/04ABBVIE : RBC Capital Adjusts AbbVie's Price Target to $135 From $129, Maintains Outperform..
MT
01/28ABBVIE : Morgan Stanley Adjusts Price Target on AbbVie to $116 From $120, Maintains Overwe..
MT
01/28ABBVIE : Berenberg Adjusts AbbVie's Price Target to $105 From $98, Reiterates Hold Rating
MT
2020ABBVIE : SVB Leerink Adjusts AbbVie's Price Target to $128 From $119, Keeps at Outperform
MT
2020ABBVIE : RBC Capital Adjusts AbbVie's Price Target to $129 From $127, Maintains Outperform..
MT
2020ABBVIE : UBS Adjusts AbbVie's Price Target to $124 From $118, Reiterates Buy Rating
MT
2020ABBVIE : Morgan Stanley Adjusts AbbVie's Price Target to $120 From $108 on 2022 Estimates,..
MT
2020ABBVIE : BMO Capital Starts AbbVie at Outperform With $123 Price Target
MT
2020ABBVIE : Bernstein Reinstates AbbVie at Outperform with $120 Price Target
MT
2020ABBVIE : Goldman Sachs Adjust Price Target for AbbVie to $103 From $96, Maintains Neutral ..
MT
2020ABBVIE : SVB Leerink Adjusts AbbVie's Price Target to $119 From $122, Keeps at Outperform
MT
2020VOYAGER THERAPEUTICS : Down 11% on End of AbbVie Collaborations
DJ
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2018ABBVIE : CFO Chase to retire by mid-year 2019
RE
2018Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
2018Citron's Left reiterates belief AbbVie shares will fall sharply
RE
2018Overshadowed by Takeda bid, Shire reports solid start to year
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018U.S. tax change to help Roche's 2018 profit growth outpace sales
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2015ABBVIE : revenue miss raises concerns over Humira sales
RE
2015Generic drugmaker Teva makes $40 billion offer for rival Mylan
RE
2015AbbVie CEO defends Pharmacyclics deal to sceptical investors
RE
2015Dealmakers in Davos see more M&A despite geopolitical risks
RE
2014ABBVIE : Jilted Shire raises guidance again after third-quarter earnings jump
RE
2014ABBVIE : cools on $55 billion Shire deal after U.S. tax changes
RE
2014AbbVie cools on $55 billion Shire deal after U.S. tax changes
RE
2014ABBVIE : cools on $55 billion Shire deal after U.S. tax changes
RE
2014Becton Dickinson to buy CareFusion for $12 billion in cash, stock
RE
2014ABBVIE : profit beats estimates on surging Humira sales
RE
2014AbbVie’s Shire merger backed with 13.5 billion pound bridge loan
RE
2014AbbVie’s Shire merger backed with 13.5 billion pounds bridge loan
RE
2014Shire ready to bow to AbbVie's increased $53 billion offer
RE
2014AbbVie forced to retract claims of Shire investor support
RE
2014Cancer drug setback tarnishes AstraZeneca's R&D claims
RE
2014Abbott to buy Latin American drugmaker CFR in $2.9 billion deal
RE
2014Abbott to buy Latin American drugmaker CFR in $2.9 billion deal
RE
2014Ablynx agrees Merck cancer deal worth up to 1.7 billion euros
RE
2013Analysis - Bayer immune to pharma's breakup bug?
RE
2013Bayer immune to pharma's breakup bug?
RE
2013Fast-growing Humira extends domination of AbbVie
RE
2013ABBOTT LABORATORIES : Abbott profit beats forecast, nutritional products strong
RE
2013Abbott to buy cataract laser, leg stent businesses
RE
2013ABBOTT LABORATORIES : Abbott results bode well for spun-off AbbVie
RE
Upcoming event on ABBVIE INC.